CA
NZ
UK
AU
IND
US
Tempest Therapeutics, Inc. filed a Form 8-K on November 6, 2026, disclosing that it received a Nasdaq deficiency notice on November 4, 2026, for failing to maintain the minimum $1.00 closing bid price requirement for its common stock.
PAID, Inc. filed a current report on November 5, 2026, disclosing that effective October 31, 2026, it extended a Forbearance Agreement with Embolx, Inc. through January 31, 2027, covering a note receivable with a principal balance of $5,967,100.
Eva Live Inc. filed a Form 8-K on November 6, 2026, disclosing a Forbearance Agreement entered into on November 5, 2026 with lender Streeterville Capital, LLC, covering two secured convertible promissory notes with an aggregate outstanding balance of $7,919,203.94, and separately announcing the launch …
News Corporation filed a Form 8-K on November 6, 2026, reporting the attachment of daily stock repurchase disclosures provided to the Australian Securities Exchange on November 5, 2026, in connection with its previously authorized $1 billion share repurchase program.
Solowin Holdings filed a Form 6-K on November 5, 2026, disclosing that it entered into a securities purchase agreement on that date to sell 1,000,000 Class B ordinary shares to Gemini Asia Holdings Limited, an entity ultimately beneficially owned by the company's Chairman and …
Invesco CurrencyShares Swiss Franc Trust filed its quarterly report on Form 10-Q with the SEC on November 6, 2026, covering the period ended September 30, 2026, and reporting total assets of $374,628,810 held primarily as interest-bearing Swiss Franc deposits.
Allogene Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 6, 2026, disclosing a net loss of $50.369 million for the three months ended September 30, 2026.
Solowin Holdings filed a Form 6-K with the SEC on November 5, 2026, disclosing a registered direct offering of 10,300,000 Class A ordinary shares at $1.20 per share to certain individual investors, with expected gross proceeds of approximately $12,360,000.
QIAGEN N.V. filed a Form 6-K with the SEC on November 5, 2026, furnishing a press release that announced unaudited financial results for the third quarter ended September 30, 2026.
Invesco CurrencyShares Euro Trust filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing financial condition and results of operations for the three and nine months ended on that date.
Please wait processing your request...